

## STROBE Checklist

**Manuscript title:** Epidemiology and Liver Transplantation Burden of Primary Biliary Cholangitis in Canada: A Retrospective Cohort Study Using National Administrative Data

STROBE Statement—checklist of items that should be included in reports of observational studies

Criteria	Item No	Recommendation	Page (Main Document)
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Pg.1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Pg.2-3, line 38-64
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Pg.4-5, line 75-110
Objectives	3	State specific objectives, including any prespecified hypotheses	Pg.4-5, line 106-110
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	Pg.5-8, line 111-173
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Pg.5-6, line 112-139
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Pg.5-6, line 112-139
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Pg.6-8, line 140-173
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Pg.5-6, line 112-139
Bias	9	Describe any efforts to address potential sources of bias	Pg.6, line 125-218; Pg. 6, line 134-139; Pg. 7, line 161-162
Study size	10	Explain how the study size was arrived at	Pg.5, line 113-16

## STROBE Checklist

**Manuscript title:** Epidemiology and Liver Transplantation Burden of Primary Biliary Cholangitis in Canada: A Retrospective Cohort Study Using National Administrative Data

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Pg.6, line 128-132
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Pg.7-8, line 156-173
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	Pg.6, line 125-218
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	Pg.7, line 160-161, 166-170
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	170
		(e) Describe any sensitivity analyses	N/A
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	As per the Methods section, all patients in the study databases were included; missing data (e.g., MELD score) was not imputed; Number of censored patients are shown in Fig.5
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Pg.8-9, line 188-196
		(b) Indicate number of participants with missing data for each variable of interest	STROBE attachment, Table 1
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Pg.10, line 218-220
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Pg.8, line 176-177; Pg. 9 line 198-199
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	N/A
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence	STROBE attachment, Table 2

## STROBE Checklist

**Manuscript title:** Epidemiology and Liver Transplantation Burden of Primary Biliary Cholangitis in Canada: A Retrospective Cohort Study Using National Administrative Data

		interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	Pg.7, line 151-154
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	Pg.10-12, Line 222-290
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Pg.12, Line 273-284
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Pg.12, Line 285-290
Generalisability	21	Discuss the generalisability (external validity) of the study results	Real-world validity: Pg.11, Line 251-261
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Pg.1-2, Line 25-28

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Websites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).